Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.65 USD
Change Today +0.17 / 0.97%
Volume 931.3K
HALO On Other Exchanges
As of 5:20 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

11388 Sorrento Valley Road

San Diego, CA 92121

United States

Phone: 858-794-8889

Fax: 858-704-8311

Halozyme Therapeutics, Inc. researches, develops, and commercializes human enzymes. The company’s proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. Hylenex Recombinant (hyaluronidase human injection) The company’s products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Hylenex recombinant is a formulation of rHuPH20 that has received the U.S. Food and Drug Administration (FDA) approval to facilitate subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and in subcutaneous urography, to improve resorption of radiopaque agents. PEGPH20 The company is developing PEGPH20 as a candidate for the systemic treatment of tumors that accumulate hyaluronic acid in combination with approved cancer therapies. The company is also developing PEGPH20, a new molecular entity that is in Phase II clinical trials for the treatment of metastatic pancreatic cancer, as well as in Phase I clinical trial for the treatment of non-small cell lung cancer. The company is investigating Hylenex recombinant for use as pre-treatment in patients with type 1 diabetes using pumps and recombinant human cathepsin L (HTI-501) for the treatment of cellulite. Agreements The company and F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche) have an agreement under which Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with up to 13 Roche target compounds (the Roche Collaboration). As of December 31, 2014, Roche has elected a total of five exclusive targets and retains the option to develop and commercialize rHuPH20 with three additional targets through the payment of annual license maintenance fees. The company and Baxter Healthcare Corporation (Baxter) has an agreement under, which Baxter obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID (HYQVIA) (the Baxter Collaboration). GAMMAGARD LIQUID is a Baxter product that is indicated for the treatment of primary immunodeficiency disorders associated with defects in the immune system. In 2012, the company and Pfizer Inc. (Pfizer) entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining its rHuPH20 enzyme with Pfizer proprietary biologics directed to up to six targets in primary care and specialty care indications. In 2014, the company and Janssen Collaboration (Janssen) entered into a collaboration and license agreement, under which Janssen has the worldwide license to develop and commercialize products combining its rHuPH20 enzyme with Janssen proprietary biologics directed to up to five targets. Customers The company’s customers include Roche; Janssen; Baxter; and Pfizer. Patents and Proprietary Rights The company’s patent portfolio includes 20 issued patents in the U.S., 80 issued patents in Europe and other countries in the world and a number of pending patent applications. The company’s issued patents would expire between 2022 and 2032. It has multiple patents and patent applications throughout the world pertaining to its recombinant human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in 2024. Manufacturing The company has existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and Cook Pharmica LLC (Cook) to produce supplies of bulk rHuPH20. The company has a commercial manufacturing and supply agreement with Baxter, a cGMP-approved manufacturing facility, under which Baxter provides the final fill and finishing steps in the producti

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $17.65 USD +0.17

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.85 USD +0.55
Valeant Pharmaceuticals International Inc C$115.35 CAD -1.01
View Industry Companies

Industry Analysis


Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.6x
Price/Book 69.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HALOZYME THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at